Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: J Thorac Cardiovasc Surg. 2015 Oct 19;151(4):969–979.e3. doi: 10.1016/j.jtcvs.2015.09.127

Figure 1.

Figure 1

Overall survival (OS). A, Entire cohort: the 5-year OS was 39% (95% CI, 28%–56%). B, Postinduction PET N2 status: the 5-year OS for N2-negative was 43% (95% CI, 22%–83%) vs 39% (95% CI, 23%–64%) for N2-avid disease (p=0.251). C, Pathologic N2 status: the 5-year OS for N2-negative was 40% (95% CI, 25%–64%) vs 38% (95% CI, 21%–67%) for N2-persistent disease (p=0.936). D, Pathologic staging: the 5-year OS for <ypIIIA was 41% (95% CI, 25%–66%) vs 37% (95% CI, 21%–66%) for ≥ypIIIA (p = 0.791).